Chemotherapy Foundation Symposium XXVI: Innovative cancer therapy for tomorrow - Chronic myelogenous leukemia: Is there hope after therapeutic failure with imatinib (Gleevec)?

Marvin M. Goldenberg, Jorges Cortes

Research output: Contribution to journalArticle

Abstract

Studies of other inhibitors, such as PHA-739358, AP-24534, and DCC-2036, are expected to begin shortly. Each agent that was described in this section offers hope in cases of treatment failure with imatinib. The major challenges are to prevent the development of imatinib resistance and to find ways to eradicate all evidence of disease in all patients.

Original languageEnglish (US)
Pages (from-to)714-719
Number of pages6
JournalP and T
Volume33
Issue number12
StatePublished - Dec 1 2008
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this